Vanguard CPV solution for injection for dogs

Authorised

- Canine parvovirus, strain NL-35-D, Live

Product identification

Medicine name:
Vanguard CPV solution for injection for dogs

Active substance:
Canine parvovirus, strain NL-35-D, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Canine parvovirus, strain NL-35-D, Live
316228000.00 50% cell culture infectious dose / 1.00 Dose

Pharmaceutical form:
Solution for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AD01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Ireland

Available in:
Ireland

Package description:
The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Pack contains 100vials of 1 ml liquid Vanguard CPV.
The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Pack contains 25vials of 1 ml liquid Vanguard CPV.
The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Pack contains 10vials of 1 ml liquid Vanguard CPV.
The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Pack contains 1vial of 1 ml liquid Vanguard CPV.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis Belgium S.A.

Marketing authorisation date:
12/09/2014

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
Health Products Regulatory Authority

Authorisation number:
VPA10387/083/001

Date of authorisation status change:
12/09/2014

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics